□本报记者 陈浩 祁道鹏 新年伊始，中原大地重点项目建设热潮涌动，国内最大的体外诊断产业园在郑州经开区加速成型。 1月13日，记者走进安图生物体外诊断产业园三期项目建设现场，热火朝天的施工场景扑面而来：主体 建筑全部竣工，内部装修紧张推进，部分员工已抢先入驻办公。 安图生物专注于体外诊断试剂和仪器的研发、制造、整合及服务，产品覆盖免疫、微生物、生化等全检 测领域，更在测序、质谱等精准诊断赛道抢先布局。截至目前，该公司产品已进驻全国2600多家三级医 院，覆盖率达64.8%；二级及以上医院终端用户超6700家，产品还远销全球100多个国家和地区，稳稳 跻身国内行业第一梯队。 在安图生物仪器生产中心，自动化流水线高速运转，机械臂精准操作，技术工人轻点屏幕，全流程数据 一目了然。"核心技术攥在自己手里，要让中国智造惠及更多患者！"张瑞峰语气坚定。 作为国内第一家在上交所主板上市的体外诊断领域研发制造型企业，安图生物连续多年研发高投入，既 啃下了技术攻关的"硬骨头"，又收获了产业升级的"甜果实"。 "十四五"期间，安图生物研发投入累计超30亿元，研发费用占比连续多年超14%，研发强度稳居行业第 一梯队。目前，公司拥有 ...

Core Insights - As of January 12, 2026, 106 A-share listed companies have released their 2025 earnings forecasts, with nearly 60% indicating positive expectations, including 60 companies expecting profit increases or recoveries, while 40 companies forecast declines or losses [1] Group 1: Positive Earnings Forecasts - The main sectors with positive earnings forecasts include pharmaceuticals, semiconductors, computers, communications, and other electronic equipment manufacturing, primarily concentrated in the ChiNext and STAR Market [1] - Companies in the non-ferrous metal mining and chemical manufacturing sectors also reported positive forecasts, influenced by rising prices of non-ferrous metals and chemical products [1] Group 2: Notable Company Performances - Huisheng Bio is expected to turn a profit in 2025, with a projected net profit of 235 million to 271 million yuan, representing a year-on-year increase of 1265.93% to 1444.54% [3] - The profit increase for Huisheng Bio is attributed to market expansion, improved production capacity, and a reduction in financial costs due to early redemption of convertible bonds [3][4] - Wanfu Bio, however, is projected to report a net loss of 46 million to 69 million yuan in 2025, marking its worst performance since its listing in 2015, with a significant decline in net profit and a first-time loss in non-recurring net profit [5][8] Group 3: Industry Challenges - Wanfu Bio's challenges stem from domestic market price reductions, changes in product structure, and increased financial burdens due to reduced capitalization of interest expenses [6][8] - The real estate sector, particularly companies like Greenland Holdings, continues to face significant challenges, with projected net losses of 16 billion to 19 billion yuan due to declining asset prices and extended project development cycles [6]

Core Viewpoint - The company YHLO (688575.SH) received a regulatory warning for misleading information disclosure related to its strategic cooperation with Shenzhen Brain Machine Star Chain Technology Co., Ltd. regarding brain-computer interface technology [2][5]. Group 1: Regulatory Issues - YHLO's announcement about the cooperation with Brain Machine Star Chain contained inconsistent statements regarding the technical approach, failing to adequately disclose risks related to collaboration feasibility and uncertainty [2]. - The Shanghai Stock Exchange issued an inquiry letter shortly after YHLO's announcement, leading to a regulatory warning for the company's then Secretary of the Board, Wang Mingyang [2]. Group 2: Company Background and Product Development - Brain Machine Star Chain was established in September 2025 with a registered capital of 5 million yuan, and its products have not yet obtained medical device registration certificates, leading to uncertainty about their approval timeline [2]. - YHLO stated that the cooperation would not have a significant impact on its business, and the development cycle for related projects is long and uncertain [2][5]. Group 3: Stock Price Movement - On January 6, YHLO's stock price rose by 6.52%, with trading volume increasing by 299% before the announcement of the strategic cooperation [4]. - Following the regulatory inquiry and a supplementary announcement, YHLO's stock price stabilized at 15.53 yuan per share by January 7, remaining unchanged from the previous closing price [6]. Group 4: Financial Performance - YHLO reported a revenue of approximately 1.287 billion yuan for the first nine months of 2025, a year-on-year decline of 7.69%, with net profit dropping by 72.36% due to reduced domestic market demand and losses from financial assets [7]. - The company plans to invest no more than 15 million yuan in Brain Machine Star Chain, which is a small proportion of its cash reserves of 466 million yuan as of September 2025 [8].

呼吸道诊断试剂是用于检测呼吸道病原体（如病毒、细菌、真菌等）以及相关炎症、生物标志物的体外诊断产品，主要应用于上呼吸道与下呼吸道感染的临床筛 查、鉴别诊断与疗效监测。此类试剂可采用多种技术平台，包括核酸检测（ PCR 、 RT-PCR 、等温扩增）、抗原 / 抗体免疫检测、多重呼吸道病原体分型试剂、 分子 POCT 快速检测卡以及炎症标志物检测试剂（如 CRP 、 PCT 等）。呼吸道诊断试剂能够快速判断常见感染源，如流感病毒、 RSV 、 SARS-CoV-2 、腺病 毒、肺炎支原体、细菌性肺炎病原等，为临床提供准确依据，有助于抗生素合理使用、降低误诊与滥用抗生素的风险。 中国呼吸道诊断试剂市场的快速发展得益于分子诊断、快速抗原检测和免疫层析技术的持续进步。高灵敏度、快速出结果和操作简便的产品，使医院、第三方实 验室及公共卫生机构能够在短时间内实现多病原检测与早期诊断。国内企业不断推进平台化、组合化产品和 POCT 设备的研发，同时引入自动化与智能化系统， 提高检测效率与标准化水平，从而推动市场需求持续增长。 随着居民健康意识提升、医院急诊和发热门诊数量增加，以及公共卫生监测和学校、企业等场所对快速筛查的需 ...

Group 1 - The core viewpoint of the news is that Zhongyuan Xiehe's stock has shown a positive trend with a 10.16% increase year-to-date and a market capitalization of 12.99 billion yuan as of January 12 [1] - The company operates in the medical and biological industry, specifically in the field of medical devices and in vitro diagnostics, with a revenue composition primarily from testing reagents (58.46%) and cell detection preparation and storage (26.49%) [1][2] - As of September 30, 2025, Zhongyuan Xiehe reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] Group 2 - The company has not distributed any dividends in the last three years, with a total payout of 37.54 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2][3] - Major shareholders include Hong Kong Central Clearing Limited, which holds 15.25 million shares, an increase of 902,300 shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Jiukang Bio has shown a positive stock performance recently, with a year-to-date increase of 6.12% and a market capitalization of 8.132 billion yuan [1] - As of January 12, Jiukang Bio's stock price was 13.87 yuan per share, with a trading volume of 61.5571 million yuan and a turnover rate of 1.06% [1] - The company primarily engages in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology testing, with 95.09% of its revenue coming from in vitro diagnostic reagents [1] Group 2 - As of September 30, Jiukang Bio reported a decrease in revenue to 1.012 billion yuan, a year-on-year decline of 18.24%, and a net profit of 272 million yuan, down 27.03% year-on-year [2] - The number of shareholders decreased by 2.48% to 18,100, while the average circulating shares per person increased by 2.54% to 23,502 shares [2] - The company has distributed a total of 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3]

Core Viewpoint - The company Aihuilong has received a regulatory warning from the Shanghai Stock Exchange due to inconsistent disclosures regarding its strategic partnership with Brain Machine Star Chain Technology, particularly concerning the technology paths involved in their collaboration [1][2]. Group 1: Regulatory Warning - Aihuilong was issued a warning letter by the Shanghai Stock Exchange for failing to provide accurate and complete information regarding its partnership with Brain Machine Star Chain, which raised concerns about potential investor misguidance [1]. - The company’s announcement about the partnership led to a significant increase in its stock price by 6.52% and a trading volume surge of 299% compared to the previous day [1]. Group 2: Partnership Details - Aihuilong signed a strategic cooperation framework agreement with Brain Machine Star Chain to collaborate on product development, market promotion, and equity investment, with Brain Machine Star Chain focusing on both non-invasive and invasive technology paths [1][2]. - Aihuilong clarified that Brain Machine Star Chain's current research products are based solely on non-invasive technology and that no invasive technology is being developed at this stage [2]. Group 3: Financial Performance - For the first three quarters of 2025, Aihuilong reported revenue of approximately 1.287 billion yuan, a year-on-year decrease of 7.69%, and a net profit of about 60.42 million yuan, down 72.36% year-on-year [3]. - The company has cash reserves of 465 million yuan [3].

Core Viewpoint - The current "brain-computer interface" is a market hotspot, attracting significant investor attention, particularly after the company's stock price rose by 6.52% with a trading volume increase of 299% compared to the previous trading day. The company is urged to ensure that disclosures related to this hot topic are accurate and complete to avoid misleading investors [2] Group 1: Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to the company, highlighting inconsistencies in the announcement regarding the technical path of its partner and insufficient risk disclosures related to collaboration uncertainties [2] - Following the announcement of a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd., the company faced immediate media scrutiny and market attention [2][3] Group 2: Partnership Details - The company clarified that the current research products of Brain Machine Starlink are based on a non-invasive technical path, with no invasive technology in development, and that some products are still in early research or pre-clinical stages [3] - The company plans to invest no more than 15 million yuan in Brain Machine Starlink, with an estimated research and development investment of around 30 million yuan for the related projects, which are still in early stages and have uncertain development timelines [3] Group 3: Financial Performance - For the first three quarters of 2025, the company's revenue was approximately 1.287 billion yuan, a year-on-year decrease of 7.69%, while net profit was about 60.42 million yuan, down 72.36% year-on-year. The company reported cash and cash equivalents of 465 million yuan [4]

Investment Rating - The report maintains an "Accumulate" rating for the in vitro diagnostics industry [7]. Core Views - The in vitro diagnostics (IVD) market is experiencing significant growth, with the domestic biochemical diagnostics sector having largely completed its localization process. The report suggests focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [4][54]. - Recent policy changes in Chongqing regarding pathology service pricing are expected to streamline and clarify pricing structures, which may enhance the role of pathology in precision medicine [4][54]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 7.81% this week, ranking 6th among 31 primary industries. The in vitro diagnostics sector specifically increased by 8.52% [9][18]. - The medical services sub-sector reported a 12.34% increase, while other related sectors also showed positive growth [18][19]. Valuation Metrics - As of the end of the week, the in vitro diagnostics sector had a PE ratio of 41.66X, with a one-year maximum of 41.97X and a minimum of 20.96X. The current PB ratio stands at 1.90X, with a one-year maximum of 2.01X and a minimum of 1.53X [3][28]. - The PE ratio increased by 3.30X and the PB ratio by 0.15X compared to the previous week [28]. Company Performance - Top-performing companies in the medical services sector include Anbiping (+39.5%), Rejing Biological (+27.1%), and Botuo Biological (+19.0%). Conversely, Mingde Biological (-2.2%) and others showed weaker performance [2][23].

Core Viewpoint - The company has been deeply engaged in the in vitro diagnostics industry for many years and possesses a rich portfolio of in vitro diagnostic reagents and instruments [1] Group 1 - The company will closely monitor industry development trends and market demands [1] - The company plans to formulate business strategies based on actual business needs and development strategies [1] - The company aims to actively seize business opportunities [1]